On June 7, 2024, Myositis Support & Understanding (MSU) and The Myositis Association (TMA) convened an Externally Led Patient Focused Drug Development (EL-PFDD) meeting on adult dermatomyositis.
Patients and care partners spoke about what matters most – and the FDA listened. See the results below.